- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Is PI-RADS Version 2.1 Outdated for Prostate MRI?
In a new point-counterpoint discussion published in the American Journal of Roentgenology, researchers debate the merits and limitations of the Prostate Imaging Reporting and Data System (PI-RADS) version 2.1.
Does the Prostate Imaging Reporting and Data System (PI-RADS) version 2.1 need an overhaul?
Debating the issue in a set of point-counterpoint articles, recently published in the American Journal of Roentgenology, researchers noted that a prevailing majority of technical specifications for the PI-RADS system haven’t changed in nearly 10 years, but the system reportedly offers a strong tool for ruling out clinically significant prostate cancer (csPCa).
Here are eight takeaways from the point-counterpoint discussion.
1. In the last decade, only 22 publications focusing on MRI have advocated for changes to the PI-RADS system and the researchers noted that only five of those publications provided metrics to support the impact of the proposed changes for the “whole spectrum of outcomes,” according to lead counterpoint author Leonardo Kayat Bittencourt, M.D., Ph.D, who is affiliated with the Department of Radiology at University Hospitals Cleveland Medical Center in Ohio, and colleagues.
2. Thirty of 35 parameters for PI-RADS technical specifications have not changed since the introduction of PI-RADS version 2 (v2) in 2015, according to the point author Tristan Barrett, MBBS, MD, who is affiliated with the Department of Radiology at the University of Cambridge and Cambridge University Hospitals NHS Foundation Trust Addenbrooke’s Hospital in Cambridge, United Kingdom.
Researchers debated the merits and drawbacks of the Prostate Imaging Reporting and Data System (PI-RADS) version 2.1 in recent point-counterpoint articles published in the American Journal of Roentgenology. (Images courtesy of Adobe Stock.)
3. Dr. Barrett noted that current Prostate Imaging Quality (PI-QUAL) recommendations suggest that meeting only seven of the aforementioned PI-RADS parameters facilitates optimal quality across T2-weighted, diffusion-weighted, and dynamic contrast-enhanced MRI sequences.
4. In contrast to a T2-weighted MRI-led approach recommended by the PI-RADS system, Dr. Barrett said recently published research points out that diffusion-weighted imaging MRI (DWI MRI) interpretation of the transition zone prior to T2WI MRI leads to a 36 percent improvement in specificity (90 percent) and a 16 percent increase in inter-reader agreement (73 percent).
5. Dr. Bittencourt and colleagues maintained that the current PI-RADS v2.1 system provides straightforward protocols and acquisition parameters that are “readily implementable” in 1.5 T or higher MRI scanners without the need for proprietary technology.
6. The current PI-RADS recommendations don’t reflect advances in signal-to-noise ratio (SNR) and spatial resolution driven by increased availability of synthetic b-value DWI MRI and the advent of deep learning reconstruction, according to Dr. Barrett.
7. Dr. Barrett noted that current PI-RADS recommendations do not provide guidance on the use of biparametric MRI (bpMRI).
8. Citing a 70-study meta-analysis published earlier this year, the Dr. Bittencourt and colleagues pointed out that the current PI-RADS system has a 93 percent sensitivity for excluding csPCa.
Prostate MRI Study Examines Key Predictors of False-Negative and False-Positive Results
February 17th 2025Researchers found that patients with high PSA density have more than double the risk of false-negative findings on prostate MRI and those with low PSA density are significantly less likely to have false-positive results.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.
What a New Meta-Analysis Reveals About PET/CT Radiotracers for csPCa
February 6th 2025The PET/CT agent 18F-PSMA-1007 offered the highest surface under the cumulative ranking curve (SUCRA) out of nine radiotracers at the patient and lesion level for detecting clinically significant prostate cancer (csPCa), according to a meta-analysis.
Can MRI-Based Deep Learning Improve Risk Stratification in PI-RADS 3 Cases?
January 30th 2025In external validation testing, a deep learning model demonstrated an average AUC of 87.6 percent for detecting clinically significant prostate cancer (csPCA) on prostate MRI for patients with PI-RADS 3 assessments.
Emerging PET Agent Garners Second FDA Fast Track Designation for Prostate Cancer Imaging
January 24th 2025In addition to an August FDA fast track designation for PSMA PET imaging in patients with suspected metastasis, the radiopharmaceutical 64Cu-SAR-bisPSMA has earned another fast track designation for imaging of biochemical recurrence.
